Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging trial of NNC0194-0499 with semaglutide in NASH
jRCT2031210294Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides, Hormonal Peptides → Native Peptides → Peptides
01
Overview
Randomised, double-blind trial of nn9500, semaglutide and cagrilintide in metabolic dysfunction-associated steatohepatitis (MASH) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Improvement in liver fibrosis and no worsening of NASH. Started Sep 2021; status: completed.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on jRCT2031210294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210294.